Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability

Neuroscience Letters

Volumn 354, Issue 3, 2004, Pages 234-238

  Blum, David ^a   Galas, Marie Christine ^a   Cuvelier, Laetitia ^a   Schiffmann, Serge N ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

3 Nitropropionic acid; Dopamine; Huntington's disease; Striatum; Substantia nigra

Indexed keywords

3 NITROPROPIONIC ACID; MAZINDOL; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL VIABILITY; CHRONIC TOXICITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0347052805     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2003.10.034     Document Type: Article

References (28)

1. Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Hayden M.R., Levine M.S. Striatal neurochemical changes in transgenic models of Huntington's disease. J. Neurosci. Res. 68:2002;716-729.
2. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23:2000;298-304.
3. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
4. Bizat N., Hermel J.M., Boyer F., Creminon C., Ouary S., Escartin C., Hantraye P., Krajewski S., Brouillet E. Calpain is a major cell death effector responsible for the selective striatal degeneration induced in vivo by 3-nitropropionate implications for Huntington's disease. J. Neurosci. 23:2003;5020-5030.
5. Blum D., Galas M.C., Gall D., Cuvelier L., Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10:2002;410-426.
6. Blum D., Gall D., Cuvelier L., Schiffmann S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport. 12:2001;1769-1772.
7. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22:2002;9122-9133.
8. Blum D., Hourez R., Galas M.C., Popoli P., Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2:2003;366-374.
9. Bohnen N.I., Koeppe R.A., Meyer P., Ficaro E., Wernette K., Kilbourn M.R., Kuhl D.E., Frey K.A., Albin R.L. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 54:2000;1753-1759.
10. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59:1999;427-468.
11. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Conde F., Palfi S., Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem. 70:1998;794-805.
12. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA. 92:1995;7105-7109.
13. El Massioui N., Ouary S., Cheruel F., Hantraye P., Brouillet E. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp. Neurol. 172:2001;172-181.
14. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 120:(Pt 3):1997;503-514.
15. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19:1999;2522-2534.
16. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 23:2000;239-245.
17. LaFontaine M.A., Geddes J.W., Butterfield D.A. 3-Nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington's disease. Neurochem. Res. 27:2002;507-511.
18. Macaya A., Burke R.E. Effect of striatal lesion with quinolinate on the development of substantia nigra dopaminergic neurons: a quantitative morphological analysis. Dev. Neurosci. 14:1992;362-368.
19. Maragos W.F., Zhu J., Chesnut M.D., Dwoskin L.P. Mitochondrial toxin inhibition of [(3)H]dopamine uptake into rat striatal synaptosomes. Biochem. Pharmacol. 63:2002;1499-1505.
20. Nakao N., Brundin P. Effects of a-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience. 76:1997;749-761.
21. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P., Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience. 97:2000;521-530.
22. Oyanagi K., Takeda S., Takahashi H., Ohama E., Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann. Neurol. 26:1989;13-19.
23. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5:2002;731-736.
24. Petersen A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 11:2002;134-146.
25. Reynolds G.P., Dalton C., Tillery C.L., Mangiarini L., Davies S.W., Bates G. Brain neurotransmitter deficits in mice transgenic for Huntington's disease mutation. J. Neurochem. 72:1999;1773-1776.
26. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler J.F. Jr, Greenamyre J.T., Snyder S.H., Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5:1999;1194-1198.
27. Sonsalla P.K., Manzino L., Sinton C.M., Liang C.L., German D.C., Zeevalk G.D. Inhibition of striatal energy metabolism produces cell loss in the ispilateral substantia nigra. Br. Res. 773:1997;223-226.
28. Zeevalk G.D., Manzino L., Hoppe J., Sonsalla P.K. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism. Eur. J. Pharmacol. 320:1997;111-119.